tbuckley/cabot-search huggingface dataset:
T cells in ventricular assist device patients.
Authors: Termuhlen Df, Pennington Dg, Roodman St, Ruzevich Sa, Swartz Mt, Reedy Je, McBride Lr, Miller Lw, Tsai Cc, Kennedy Dj
Journal: Circulation (1989)

Levels of T lymphocytes were measured in 20 consecutive patients, 18 men and two women, supported with ventricular assist devices or an artificial heart. Indications for support were bridge to transplantation (n = 10), postcardiotomy cardiogenic shock (n = 8), and acute myocardial infarction shock (n = 2). Control levels were from healthy volunteers not undergoing cardiac operation. Preoperatively, numbers of total lymphocytes and subclasses CD3, CD4, and CD8, as well as the interleukin-2 receptors (IL2R), were the same as controls (cells/microliters): lymphocytes, 1,940; CD3, 1,413 +/- 410; CD4, 894 +/- 318; CD8, 490 +/- 185; IL2R, 96. From implant to postoperative day 5, levels were below control values (p less than 0.001), reaching a nadir on postoperative day 2 (lymphocytes, 896 +/- 599; CD3, 489 +/- 267; CD4, 309 +/- 207; CD8, 183 +/- 107; IL2R, 43 +/- 47). Data from 10 patients (group 1) who survived (four weaned from cardiopulmonary bypass, six transplanted) were compared with those from 10 patients (group 2) who died of multiorgan failure, sepsis, or both. From preimplant through postoperative day 6, levels did not differ between groups. However, from postoperative day 7 to the last day of ventricular support (group 1, 24-90 days; group 2, 7-29 days), group 1 levels (lymphocytes, 2,364 +/- 618; CD3, 1,825 +/- 553; CD4, 1,013 +/- 187; CD8, 796 +/- 402) were significantly above (p less than 0.01) group 2 levels (lymphocytes, 1,290 +/- 463; CD3, 746 +/- 295; CD4, 534 +/- 253; CD8, 221 +/- 106). These data indicate that lymphocytes and particularly T cells 1) decrease after ventricular assist device insertion, reaching a nadir at postoperative day 2, 2) return to control values after patients whose clinical status improves, and 3) remain low in severely ill patients. T-cell depression in ventricular assist device patients is related to the severity of the patient's condition rather than the presence of the device.
Infectious Diseases. Their Etiology, Diagnosis and Treatment.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phencyclidine in umbilical cord blood: preliminary data
Authors: K R Kaufman, R A Petrucha, F N Pitts, E R Kaufman
Journal: American Journal of Psychiatry (1983)

The epidemic abuse of phencyclidine (PCP) has become a major psychiatric issue within the past decade. With the assistance of highly sensitive capillary gas chromatographic-nitrogen detector measurements, PCP's true pervasiveness is only now being appreciated. To further quantitate the severity of the problem, the authors analyzed samples of umbilical cord blood from 200 patients on the obstetrics service of a major university medical center. Preliminary results revealed that 24 (12%) of the samples were positive for PCP (.10-5.80 ng/ml). The authors discuss the significance of this finding with regard to psychiatry, obstetrics, pediatrics, and juvenile law.
Scintigraphic demonstration of the origin of postoperative bile leak.
Authors: N. WALGRAEVE, A. VAN DEN EECKHAUT, F. DE GEETER
Journal: Clinical Nuclear Medicine (2001)

WALGRAEVE, N. M.D.; VAN DEN EECKHAUT, A. M.D., AND; DE GEETER, F. M.D., Ph.D. Author Information
Elevation of brain neuroleptic/dopamine receptors in schizophrenia
Authors: T Lee, P Seeman
Journal: American Journal of Psychiatry (1980)

To test the dopamine hypothesis of schizophrenia the authors measured specific 3H-neuroleptic/dopamine binding sites in three dopamin-rich regions of 59 postmortem normal human brains and 50 postmortem brains from schizophrenic patients using 3H-haloperidol and 3H-spiperone. The binding of 2 nM 3H-haloperidol and of 1 nM 3H-spiperone was significantly elevated in the brains from schizophrenic patients. The brain regions from patients who had no history of being treated with neuroleptic drugs also exhibited significantly higher binding of the 3H-neuroleptics. These results are compatible with the hypothesis that schizophrenia may be associated with an overactivity of postsynaptic dopamine receptors.
Educational Council for Foreign Medical Graduates
Authors: E W SCHNOOR
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Red hair and hyperpigmentation in a black man after chemotherapy.
Authors: C Loureiro, P S Gill, M Rarick, A M Levine
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.10.1705 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3655865 Red hair and hyperpigmentation in a black man after chemotherapy. C LoureiroxC LoureiroSearch for articles by this author , P S GillxP S GillSearch for articles by this author , M RarickxM RarickSearch for articles by this author , A M LevinexA M LevineSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.10.1705 PDF "Red hair and hyperpigmentation in a black man after chemotherapy.." Journal of Clinical Oncology, 5(10), pp. 1705–1706© 1987 by American Society of Clinical Oncology
EPN-06SUCCESSFUL ESTABLISHMENT OF A PANEL OF PATIENT-SPECIFIC ORTHOTOPIC XENOGRAFT MODELS OF RECURRENT EPENDYMOMA
Authors: Huiyuan Zhang, Sibo Zhao, Lin Qi, Yuchen Du, Holly Lindsay, Frank K. Braun, Mari Kogiso, Patricia Baxter, Jack Su, Xiao-Nan Li
Journal: Neuro-Oncology (2016)
UK minister lobbied EU for lighter regulation of drugs and devices
Authors: Deborah Cohen
Journal: BMJ (2016)

The UK government has been lobbying the European Commission to adopt a more relaxed approach to regulating drugs, devices, and food, a letter seen by The BMJ has shown.

George Freeman, the UK life sciences minister with responsibilities including the Medicines and Healthcare Products Regulatory Agency and the National Institute for Health and Care Excellence, wrote to the European Union’s (EU) research, science and innovation commissioner, Carlos Moedas, late last year to urge him to “tackle the increasingly precautionary ‘anti-science’ trend in EU legislation” that he said was stifling innovation.

Freeman said that regulation needed to change “to attract significant inward investment, attract industry collaboration, and support new business growth.”

Citing a 2015 report from financial consultants Capital Economics, Freeman wrote that the “bioeconomy”—which included medicine, food, biotechnology, and agrichemicals—provided …
Primary affective disorder in relatives of patients with anorexia nervosa
Authors: A Winokur, V March, J Mendels
Journal: American Journal of Psychiatry (1980)

The authors examined the incidence of primary affective disorder (PAD) in relatives of 25 patients with anorexia nervosa and of 25 normal control subjects. Among the relatives of patients with anorexia nervosa, 22% (N = 43) had histories of PAD, while only 10% (N = 17) of the relatives of controls had such histories. Among the PAD relatives of anorectic probands, 34 had histories of unipolar depression and 9 of bipolar affective disorder. These findings provide further evidence of a possible relationship between anorexia nervosa and affective illness.
NU-16PATIENT SAFETY MAY BE IMPROVED USING A DOSE CALCULATING-AND-ROUNDING ELECTRONIC CHEMOTHERAPY ORDER ENTRY AND VERIFICATION SYSTEM WITH CLINICAL DECISION SUPPORT SYSTEM (CDSS) FEATURES IN THE PEDIATRIC SETTING
Authors: Stephen Gilheeney, Jill Ackerman, Jennifer De Luca, Donna Robinson, Raymond Muller, Nancy Sklarin
Journal: Neuro-Oncology (2016)

BACKGROUND: Patient safety and reduced risk of errors in prescribing are of great importance.Computerized physician order entry (CPOE) is thought to reduce the risk of errors, especially when combined with a clinical decision support system.METHODS: Beginning January 2010, we rolled out a software program with modifications directly from the vendor, in a disease team step-wise fashion, outpatient finishing in December 2010 and inpatient finishing in May 2011.This process made our department the first in the country to implement electronic dose calculation and electronic four layer verification.Our order entry system included multiple mandatory fields to ensure order completeness, tall man lettering to ensure correct drug selection and various dose calculation options when required (e.g.Calvert vs. mg/kg).Clinical decision support features included dose modification instructions.We then investigated prescribing, dispensing, and treatment error rates in the three years prior to and the three years after rollout as monitored by our voluntary error reporting system.RESULTS: Beginning in 2012, our department reported decreasing level 0 (near miss) and level 1 (no harm) errors reported over three years (2012 through 2014): Level 0 ¼ 68 to 29 over two years and Level 1 ¼ 17 to 10 over two years.In the three years since implementation, no temporary harm errors were reported versus two in the three years before.Overall error rate was 0.04%.CONCLUSIONS: The type of system as described above appears to help decrease reported near-misses and errors in a medical culture increasingly concerned with patient safety.
EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma
Authors: Junli Yan, Boheng Li, Baohong Lin, Pei Tsung Lee, Tae-Hoon Chung, Joy Tan, Chonglei Bi, Xue Ting Lee, Viknesvaran Selvarajan, Siok-Bian Ng, Henry Yang, Qiang Yu, Wee-Joo Chng
Journal: Blood (2016)
Case 35-1989
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, Jonathan R. Diamond, Robert B. Colvin
Journal: New England Journal of Medicine (1989)

Presentation of CaseA 25-year-old man was admitted to the hospital because of abdominal pain, chills, and fever.The patient was black and a native of Haiti, who immigrated to this country four years earlier and attended college. Two months before admission he returned to Haiti for a one-month visit. Twenty-four days before entry he experienced the sudden onset of diffuse, crampy abdominal pain, accompanied by fever, chills, and sweats. He was seen at another hospital, where erythromycin was prescribed, and he felt improved after three or four days. Eighteen days before admission chills, fever, and sweats recurred, with a . . .
EPN-14PEDIATRIC EPENDYMOMA: MULTI-INSTITUTIONAL EXPERIENCE REVEALS POOR LONG-TERM OVERALL SURVIVAL DESPITE FAVORABLE FIVE-YEAR OUTCOMES
Authors: Amanda Marinoff, Dongjing Guo, Clement Ma, Matija Snuderl, Karen Wright, Peter Manley, Hayley Malkin, Nicole Ullrich, Karen Marcus, Liliana Goumnerova, Wendy London, Jason Fangusaro, Mark Kieran, Susan Chi, Pratiti Bandopadhayay
Journal: Neuro-Oncology (2016)
MB-38ADJUVANT RADIOTHERAPY PATTERNS OF CARE AND SURVIVAL IMPLICATIONS FOR MEDULLOBLASTOMA IN YOUNG CHILDREN
Authors: Benjamin H. Kann, Henry S. M. Park, Nataniel H. Lester-Coll, Debra N. Yeboa, Viviana Benitez, Ranjit Bindra, Atif J. Khan, Asher M. Marks, Kenneth Roberts
Journal: Neuro-Oncology (2016)
AHA/ACCF/HRS Recommendations for the Standardization and Interpretation of the Electrocardiogram
Authors: Galen S. Wagner, Peter Macfarlane, Hein Wellens, Mark Josephson, Anton Gorgels, David M. Mirvis, Olle Pahlm, Borys Surawicz, Paul Kligfield, Rory Childers, Leonard S. Gettes
Journal: Circulation (2009)

The American Heart Association, the American College of Cardiology, and the Heart Rhythm Society make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel.Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived
Family diagnoses missed on a clinical inpatient service
Authors: N J Baker, S L Berry, L E Adler
Journal: American Journal of Psychiatry (1987)

Methods for taking family psychiatric histories have been developed primarily for research rather than clinical settings. The authors compared family histories obtained independently by a research team and by PGY-3 residents on 52 consecutively admitted adult psychiatric inpatients. In contrast to the residents, the research team used a family tree, screening questions, and a structured interview based on diagnostic criteria and identified more than four times as many diagnoses in relatives as did the residents. The results demonstrate that a family history strategy derived from research methodology significantly enhances the gathering of important diagnostic information in a clinical inpatient setting.
HG-102BER INVOLVEMENT IN HIGH GRADE GLIOMAS (HGG) AND DIFFUSE INTRAPONTINE GLIOMAS (DIPG): A NEW OPPORTUNITY OF TARGETED THERAPIES
Authors: Marie Litzler, Christelle Lasthaus, Aurelia Nguyen, Aurelie Durand, Sarah Jannier, Dominique Guenor, Natacha Entz-Werle
Journal: Neuro-Oncology (2016)
Cancer-associated hemolytic uremic syndrome: a possible role of mitomycin in relation to Shiga-like toxins.
Authors: D W Acheson, A Donohue-Rolfe
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.12.1943 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2511278 Cancer-associated hemolytic uremic syndrome: a possible role of mitomycin in relation to Shiga-like toxins. D W AchesonxD W AchesonSearch for articles by this author , A Donohue-RolfexA Donohue-RolfeSearch for articles by this author https://doi.org/10.1200/JCO.1989.7.12.1943 PDF "Cancer-associated hemolytic uremic syndrome: a possible role of mitomycin in relation to Shiga-like toxins.." Journal of Clinical Oncology, 7(12), p. 1943© 1989 by American Society of Clinical Oncology
A Retrospective Comparative Study Of Intrinsic Moleculer Breast Cancer Subtypes Between Young And Elderly Women With Breast Cancer.
Authors: Gulcan Bulut, Zeki Gokhan Surmeli, Mustafa Sahbazlar, Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Saziye Burcak Karaca
Journal: Journal of Clinical Oncology (2016)

e12063 Background: Age is an important prognostic factor in breast cancer. Both younger and older patients have a higher risk of mortality. In this study we examined the intrinsic breast cancer subtypes and survival outcomes in breast cancer patients aged < 35 years > 75 years. Methods: Medical records of patients with breast cancer who were aged < 35 or > 75 years at diagnosis were retrospectively reviewed. Intrinsic breast cancer subtypes were determined in accordance with St. Gallen surrogate molecular subtype definitions. Results: 212 patients aged < 35 and 75 patients aged > 75 were included. Median age was 33.2 (range 21 – 34.9) in the younger group and 77.8 (range 75 – 88.1) in the older group. 9.4% of younger group and 18.3% of older patients were metastatic at diagnosis (p:0.04). T3 or T4 tumors were present in 19.8% and 10% of patients in younger and older patients, respectively (p:0.078). N2/N3 disease was present in 45% of younger and 50.8% of older groups. Luminal A was the most common subtype (40.5%) in the older group, whereas luminal B was the most common subtype (50.6%) in the younger group (p: < 0.001). Frequency of HER2 positive (11.1% in younger vs. 17.6% in older) and triple-negative subtypes (21% in younger vs. 13.5% in older) were not significantly different. In both younger and older groups, breast cancer specific survival was superior in luminal (A+B) subtype compared to HER2 positive and triple-negative subtypes. Conclusions: Breast cancer subtype frequencies differ between younger ( < 35 years) and older ( > 75 years) patients. The most common subtypes are luminal A in older patients and luminal B in younger patients. For both older and younger patients, breast cancer subtypes have an important prognostic impact
Comparison of Viral Marker Proteins in Murine Leukemia Virus and Mouse Uterus
Authors: J. E. Strickland, P. D. Kind, A. K. Fowler, A. Hellman
Journal: JNCI Journal of the National Cancer Institute (1974)

RNA-directed DNA polymerase and group-specific antigen were found in uteri of NIH Swiss mice in response to estrogen treatment. The viral markers from the uterus sedimented more rapidly on glycerol gradients than did the corresponding proteins from Rauscher leukemia virus, which indicated that the uterine proteins were of larger molecular weight. Template requirements of the polymerases from uterus and virus were similar, and both enzymes were inhibited by immunoglobulin G prepared against purified murine leukemia viral polymerase.
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
Authors: Cora Sternberg, Andrew Armstrong, Roberto Pili, Siobhan Ng, Robert Huddart, Neeraj Agarwal, Denis Khvorostenko, Olexiy Lyulko, Arija Brize, Nicholas Vogelzang, Rémy Delva, Mihai Harza, Anastasios Thanos, Nicholas James, Patrick Werbrouck, Martin Bögemann, Thomas Hutson, Piotr Milecki, Simon Chowdhury, Enrique Gallardo, Gilberto Schwartsmann, Jean-Christophe Pouget, Frédérique Baton, Thore Nederman, Helen Tuvesson, Michael Carducci
Journal: Journal of Clinical Oncology (2016)

Purpose Tasquinimod, a novel oral therapy targeting the tumor microenvironment, significantly improved progression-free survival (PFS) in a randomized, placebo-controlled phase II trial in men with metastatic castration-resistant prostate cancer (mCRPC). This phase III study was conducted to confirm the phase II results and to detect an overall survival (OS) benefit. Patients and Methods Men with chemotherapy-naïve mCRPC and evidence of bone metastases were assigned (2:1) to receive tasquinimod once per day or placebo until progression or toxicity. The primary end point was radiographic PFS (rPFS; time from random assignment to radiologic progression or death) per Prostate Cancer Working Group 2 criteria and RECIST 1.1. The study had 99.9% power to detect an rPFS hazard ratio (HR) of 0.6 with a two-sided alpha error of .05 and 80% power to detect a target HR of 0.8 for OS, the key secondary end point. Results In all, 1,245 patients were randomly assigned to either tasquinimod (n = 832) or placebo (n = 413) between March 2011 and December 2012 at 241 sites in 37 countries. Baseline characteristics were balanced between groups: median age, 71 years; Karnofsky performance status ≥ 90%, 77.3%; and visceral metastases, 21.1%. Estimated median rPFS by central review was 7.0 months (95% CI, 5.8 to 8.2 months) with tasquinimod and 4.4 months (95% CI, 3.5 to 5.5 months) with placebo (HR, 0.64; 95% CI, 0.54 to 0.75; P &lt; .001). Median OS was 21.3 months (95% CI, 19.5 to 23.0 months) with tasquinimod and 24.0 months (95% CI, 21.4 to 26.9 months) with placebo (HR, 1.10; 95% CI, 0.94 to 1.28; P = .25). Grade ≥ 3 adverse events were more frequent with tasquinimod (42.8% v 33.6%), the most common being anemia, fatigue, and cancer pain. Conclusion In chemotherapy-naïve men with mCRPC, tasquinimod significantly improved rPFS compared with placebo. However, no OS benefit was observed.
Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers
Authors: Louise K Mercer, Johan Askling, Pauline Raaschou, William G Dixon, Lene Dreyer, Merete Lund Hetland, Anja Strangfeld, Angela Zink, Xavier Mariette, Axel Finckh, Helena Canhao, Florenzo Iannone, Jakub Zavada, Jacques Morel, Jacques-Eric Gottenberg, Kimme L Hyrich, Joachim Listing
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Some studies have reported a possible association between exposure to tumour necrosis factor (TNF) inhibitors and an increased risk of melanoma. The aim of this study was to investigate the incidence of invasive cutaneous melanomas in patients with rheumatoid arthritis (RA) treated with TNF inhibitors (TNFi), other biologic disease modifying drugs and non-biologic therapy. <h3>Methods</h3> Eleven biologic registers from nine European countries participated in this collaborative project. According to predefined exposure definitions, cohorts of patients with RA were selected. Using the country-specific general population of each register as reference, age, sex and calendar year standardised incidence ratios (SIRs) of invasive histology-confirmed cutaneous melanoma were calculated within each register. Pooled SIR and incidence rate ratios (IRRs) comparing biologic cohorts to biologic-naïve were calculated across countries by taking the size of the register into account. <h3>Results</h3> Overall 130 315 RA patients with a mean age of 58 years contributing 579 983 person-years were available for the analysis and 287 developed a first melanoma. Pooled SIRs for biologic-naïve, TNFi and rituximab-exposed patients were 1.1 (95% CI 0.9 to 1.4), 1.2 (0.99 to 1.6) and 1.3 (0.6 to 2.6), respectively. Incidence rates in tocilizumab and abatacept-exposed patients were also not significantly increased. IRR versus biologic-naïve patients were: TNFi 1.1 (95% CI 0.8 to 1.6); rituximab 1.2 (0.5 to 2.9). <h3>Conclusions</h3> This large European collaborative project did not confirm an overall increased risk of melanoma following exposure to TNFi.